Duration of the study. The active study phase for each patient is 180 days. Enrolment is expected to begin in Q1 2008; the study is expected to end ▇▇ ▇▇▇▇.
Appears in 5 contracts
Sources: License and Commercialization Agreement (Bellerophon Therapeutics, Inc.), License and Commercialization Agreement (Bellerophon Therapeutics LLC), License and Commercialization Agreement (Bellerophon Therapeutics LLC)
Duration of the study. The active study phase for each patient is 180 days. Enrolment is expected to begin in Q1 2008; the study is expected to end ▇▇ ▇▇▇▇.. Annotated Protocol incorporating Amendment 1, Amendment 2, Amendment 3, and Amendment 4 01 December 2008 Protocol BL-1040.01, Version 5.00 Safety and Feasibility study of BL-1040 Final CONFIDENTIAL
Appears in 2 contracts
Sources: License and Commercialization Agreement (BioLineRx Ltd.), License and Commercialization Agreement (BioLineRx Ltd.)